Geode Capital Management LLC Increases Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)

Geode Capital Management LLC increased its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 3.6% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 1,008,214 shares of the company's stock after purchasing an additional 35,196 shares during the period. Geode Capital Management LLC owned approximately 1.18% of CRISPR Therapeutics worth $47,383,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Main Management ETF Advisors LLC purchased a new position in shares of CRISPR Therapeutics during the third quarter worth $693,000. XTX Topco Ltd lifted its stake in CRISPR Therapeutics by 294.0% during the 3rd quarter. XTX Topco Ltd now owns 30,022 shares of the company's stock worth $1,410,000 after acquiring an additional 22,402 shares in the last quarter. State Street Corp boosted its holdings in CRISPR Therapeutics by 25.0% during the 3rd quarter. State Street Corp now owns 2,992,988 shares of the company's stock valued at $140,611,000 after acquiring an additional 599,304 shares during the period. Readystate Asset Management LP acquired a new position in CRISPR Therapeutics in the 3rd quarter valued at about $336,000. Finally, Reynders McVeigh Capital Management LLC increased its stake in CRISPR Therapeutics by 4.3% during the third quarter. Reynders McVeigh Capital Management LLC now owns 119,586 shares of the company's stock worth $5,618,000 after purchasing an additional 4,913 shares during the period. Institutional investors and hedge funds own 69.20% of the company's stock.

Analysts Set New Price Targets

Several research firms have recently commented on CRSP. Barclays lowered their price objective on shares of CRISPR Therapeutics from $59.00 to $55.00 and set an "equal weight" rating for the company in a research note on Wednesday, November 6th. JMP Securities restated a "market outperform" rating and issued a $86.00 price target on shares of CRISPR Therapeutics in a research note on Friday. StockNews.com raised CRISPR Therapeutics to a "sell" rating in a research report on Wednesday, December 11th. Chardan Capital reiterated a "buy" rating and issued a $94.00 target price on shares of CRISPR Therapeutics in a report on Tuesday, December 10th. Finally, Royal Bank of Canada restated a "sector perform" rating and set a $53.00 price target on shares of CRISPR Therapeutics in a report on Wednesday, November 6th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and nine have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $77.93.

CRISPR Therapeutics Stock Up 1.1 %

CRSP traded up $0.46 during trading on Tuesday, hitting $40.94. 759,865 shares of the stock were exchanged, compared to its average volume of 1,519,722. The firm has a market capitalization of $3.49 billion, a P/E ratio of -14.47 and a beta of 1.62. The stock has a fifty day moving average price of $48.30 and a two-hundred day moving average price of $50.52. CRISPR Therapeutics AG has a 1-year low of $39.41 and a 1-year high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last announced its earnings results on Tuesday, November 5th. The company reported ($1.01) EPS for the quarter, beating analysts' consensus estimates of ($1.42) by $0.41. The business had revenue of $0.60 million during the quarter, compared to analysts' expectations of $6.65 million. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. During the same period in the prior year, the company earned ($1.41) earnings per share. Analysts predict that CRISPR Therapeutics AG will post -5.13 EPS for the current year.

Insider Transactions at CRISPR Therapeutics

In related news, General Counsel James R. Kasinger sold 1,089 shares of CRISPR Therapeutics stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $46.28, for a total value of $50,398.92. Following the sale, the general counsel now directly owns 62,597 shares in the company, valued at $2,896,989.16. The trade was a 1.71 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Samarth Kulkarni sold 4,293 shares of the business's stock in a transaction on Monday, October 14th. The stock was sold at an average price of $46.28, for a total transaction of $198,680.04. Following the sale, the chief executive officer now owns 226,540 shares in the company, valued at $10,484,271.20. The trade was a 1.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 50,382 shares of company stock worth $2,744,179 over the last 90 days. 4.10% of the stock is currently owned by insiders.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.